Los Angeles Capital Management LLC Acquires 42,338 Shares of Encompass Health Co. (NYSE:EHC)

Los Angeles Capital Management LLC lifted its position in Encompass Health Co. (NYSE:EHC) by 532.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 50,290 shares of the company’s stock after acquiring an additional 42,338 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Encompass Health were worth $4,860,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Crossmark Global Holdings Inc. boosted its holdings in shares of Encompass Health by 8.3% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 7,952 shares of the company’s stock worth $769,000 after buying an additional 612 shares during the last quarter. Verdence Capital Advisors LLC lifted its holdings in Encompass Health by 4.6% during the third quarter. Verdence Capital Advisors LLC now owns 3,670 shares of the company’s stock valued at $355,000 after purchasing an additional 160 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Encompass Health by 9.1% in the third quarter. QRG Capital Management Inc. now owns 15,672 shares of the company’s stock worth $1,515,000 after buying an additional 1,307 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Encompass Health by 104.7% in the third quarter. Harbor Capital Advisors Inc. now owns 73,272 shares of the company’s stock worth $7,081,000 after buying an additional 37,473 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Encompass Health by 5.5% in the third quarter. Janney Montgomery Scott LLC now owns 11,357 shares of the company’s stock worth $1,098,000 after buying an additional 597 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Up 0.1 %

Shares of NYSE EHC opened at $103.27 on Tuesday. Encompass Health Co. has a one year low of $63.01 and a one year high of $104.55. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.35. The firm’s 50 day simple moving average is $95.71 and its two-hundred day simple moving average is $89.84. The stock has a market capitalization of $10.40 billion, a P/E ratio of 24.94, a PEG ratio of 1.36 and a beta of 0.88.

Encompass Health (NYSE:EHC) last issued its earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping the consensus estimate of $0.94 by $0.09. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the previous year, the firm earned $0.86 earnings per share. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, analysts expect that Encompass Health Co. will post 4.29 EPS for the current fiscal year.

Encompass Health declared that its Board of Directors has approved a stock repurchase program on Wednesday, July 24th that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 5.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Thursday, January 2nd. Encompass Health’s payout ratio is 16.43%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Barclays upped their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Truist Financial restated a “buy” rating and issued a $116.00 price objective (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. UBS Group upped their price objective on shares of Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. KeyCorp upped their price objective on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Finally, Stephens restated an “overweight” rating and issued a $105.00 price objective on shares of Encompass Health in a research report on Tuesday, August 6th. Nine equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.